FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for Stivarga (regorafenib) from Bayer, expanding its approved uses.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Unresectable Hepatocellular Carcinoma
• Unresectable or Metastatic Gastrointestinal Stromal Tumor

Drugs mentioned

• Stivarga (regorafenib)

Snippet

SUPPL AP for STIVARGA (REGORAFENIB)